Ingalls & Snyder LLC purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 16,869 shares of the life sciences company's stock, valued at approximately $2,349,000.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Annis Gardner Whiting Capital Advisors LLC purchased a new position in Illumina during the third quarter worth about $30,000. State of Wyoming purchased a new position in Illumina during the second quarter worth about $32,000. Quent Capital LLC boosted its stake in Illumina by 71.2% in the third quarter. Quent Capital LLC now owns 250 shares of the life sciences company's stock valued at $34,000 after acquiring an additional 104 shares during the last quarter. VisionPoint Advisory Group LLC boosted its stake in Illumina by 344.6% in the third quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company's stock valued at $34,000 after acquiring an additional 193 shares during the last quarter. Finally, ST Germain D J Co. Inc. purchased a new position in Illumina in the second quarter valued at about $36,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.
Illumina Price Performance
Illumina stock traded down $3.63 during midday trading on Friday, reaching $127.07. 1,629,452 shares of the stock were exchanged, compared to its average volume of 1,567,804. The company's fifty day moving average is $135.77 and its 200-day moving average is $128.47. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66. The firm has a market cap of $20.24 billion, a PE ratio of -17.31 and a beta of 1.19. Illumina, Inc. has a 52 week low of $89.00 and a 52 week high of $232.88.
Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, topping analysts' consensus estimates of $0.01 by $0.13. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The business had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same quarter in the prior year, the firm posted $0.14 EPS. Illumina's revenue was up 3.6% on a year-over-year basis. On average, sell-side analysts forecast that Illumina, Inc. will post 0.91 EPS for the current year.
Insiders Place Their Bets
In related news, CEO Jacob Thaysen purchased 7,330 shares of the business's stock in a transaction on Thursday, February 22nd. The stock was acquired at an average price of $135.29 per share, with a total value of $991,675.70. Following the purchase, the chief executive officer now directly owns 14,861 shares in the company, valued at $2,010,544.69. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.13% of the company's stock.
Analyst Upgrades and Downgrades
ILMN has been the topic of a number of research analyst reports. HSBC cut shares of Illumina from a "buy" rating to a "hold" rating in a research note on Tuesday, January 16th. TD Cowen cut shares of Illumina from an "outperform" rating to a "market perform" rating and set a $144.00 target price on the stock. in a research note on Thursday, January 4th. Scotiabank upgraded shares of Illumina from a "sector perform" rating to a "sector outperform" rating and set a $185.00 target price on the stock in a research note on Monday, December 18th. Sanford C. Bernstein upgraded shares of Illumina from an "underperform" rating to a "market perform" rating in a research note on Friday, December 15th. Finally, StockNews.com raised shares of Illumina from a "hold" rating to a "buy" rating in a research report on Friday, February 16th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $167.70.
Read Our Latest Research Report on Illumina
Illumina Profile
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Featured Articles
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
